Vaccine Makers Down on FDA Meeting, Novavax Most at Risk

InvestorPlace2022-04-08

Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（7）

Solomontan99
·2022-04-08
Novavex as good as MRNA?
Reply
2
Report
SSVC
·2022-04-08
K
Reply
1
Report
Kiwii
·2022-04-08
hallo
Reply
2
Report
LeeWan
·2022-04-08
Ok
Reply
1
Report
Bodoh
·2022-04-08
Right
Reply
2
Report
DiAngel
·2022-04-08
But no news about Novavax in SG. 😓😢😭 i was waiting desperately for it.. 我等到花兒也謝了🌹🥀
Reply
9
Report
TaiJin
·2022-04-08
[Miser]
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1120806979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-08 10:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120806979","market":"us","top_or_hot":-1,"title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","media":"InvestorPlace","content":"<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","article_id":"1120806979","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","pubTimestamp":1649384984,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"疫苗制造商在美国食品和药物管理局会议上倒下，诺瓦克斯风险最大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9015989341,"gmtCreate":1649408931183,"gmtModify":1676534507562,"author":{"id":"3586330528378121","authorId":"3586330528378121","name":"Solomontan99","avatar":"https://static.tigerbbs.com/ae09f7a70bb7992c56a1be3b990b5332","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Novavex as good as MRNA?","listText":"Novavex as good as MRNA?","text":"Novavex as good as MRNA?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015989341","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015010988,"gmtCreate":1649390303438,"gmtModify":1676534504598,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015010988","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015097385,"gmtCreate":1649388435942,"gmtModify":1676534504291,"author":{"id":"3579735899676546","authorId":"3579735899676546","name":"Kiwii","avatar":"https://community-static.tradeup.com/news/c31b2d8301c0e367c9f368c3506dad90","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"hallo","listText":"hallo","text":"hallo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015097385","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015098237,"gmtCreate":1649387679655,"gmtModify":1676534504196,"author":{"id":"3558097748623340","authorId":"3558097748623340","name":"LeeWan","avatar":"https://static.tigerbbs.com/88769849d29a340fce73355c249755a4","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015098237","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015007020,"gmtCreate":1649386939188,"gmtModify":1676534504055,"author":{"id":"3559859558754319","authorId":"3559859558754319","name":"Bodoh","avatar":"https://static.tigerbbs.com/349218ea2852130ca86ce660b4aa2d59","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Right","listText":"Right","text":"Right","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015007020","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9015004898,"gmtCreate":1649386821337,"gmtModify":1676534504039,"author":{"id":"4100833454173050","authorId":"4100833454173050","name":"DiAngel","avatar":"https://community-static.tradeup.com/news/f7c2ee91188421bf874cdbc97fb77886","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"But no news about Novavax in SG. 😓😢😭 i was&nbsp;waiting desperately for it.. 我等到花兒也謝了🌹🥀","listText":"But no news about Novavax in SG. 😓😢😭 i was&nbsp;waiting desperately for it.. 我等到花兒也謝了🌹🥀","text":"But no news about Novavax in SG. 😓😢😭 i was waiting desperately for it.. 我等到花兒也謝了🌹🥀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015004898","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9015009191,"gmtCreate":1649385942022,"gmtModify":1676534503871,"author":{"id":"3585363622677550","authorId":"3585363622677550","name":"TaiJin","avatar":"https://static.tigerbbs.com/24d2d840485600ee9789f516e956a70f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015009191","repostId":1120806979,"repostType":4,"repost":{"id":"1120806979","pubTimestamp":1649384984,"share":"https://www.laohu8.com/m/news/1120806979?lang=&edition=full","pubTime":"2022-04-08 10:29","market":"us","language":"en","title":"Vaccine Makers Down on FDA Meeting, Novavax Most at Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1120806979","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meet","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the <b>U.S. Food and Drug Administration</b>(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.</p><p>The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.</p><p>Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.</p><p>Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.</p><p>In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.</p><p>The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Makers Down on FDA Meeting, Novavax Most at Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Makers Down on FDA Meeting, Novavax Most at Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 10:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting ...</p>\n\n<a href=\"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/vaccine-makers-down-on-fda-meeting-nvax-stock-most-at-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120806979","content_text":"Novavax(NASDAQ:NVAX) and other vaccine makers are dropping in anticipation of an advisory panel meeting of the U.S. Food and Drug Administration(FDA) regarding booster shots. This is a panel meeting of outside experts. The topic? To whom and when should a second round of covid-19 booster shots be administered to.The FDA already authorized another round of boosters for people 50 and older, and those with certain immunocompromising conditions. Vaccine makers are hoping that the FDA would further expand this recommendation.Out of the vaccine manufacturers, this news in my view, would most impact NVAX stock. The company is late to the party and has not yet received FDA approval for its vaccine. Named NVX-CoV2373, the company’s protein-based shot is still undergoing Emergency Use Authorization (EUA) in the U.S. This is on the heels of numerous delays.Time is of the essence for Novavax. Other vaccine manufacturers have successfully deployed their vaccines and are reaping great profits. Soon the market for COVID-19 vaccines will shrink to almost nothing once everyone who wanted a shot has already gotten one.In late March, Novavax scored a couple of huge wins. The company submitted a request to the European Union to allow its vaccine to be used on young people aged 12-17. Its vaccine has also recently become available in Canada. With the continued delay in U.S. approval, Novavax is pinning its hope on the rest of the world. Its vaccines are now available in Europe, Australia, Indonesia and South Korea.The company is looking to reach revenues of$4 billion to $5 billion. Only time will tell whether it can hit that amount – especially since the US market remains closed to them. NVAX stock dropped over 12% on Tuesday and continues to be on a downtrend. It broke its support base of $67 and is now at an all-time low for the year of $57.67 and dropping. It’s hard to see this support holding given the continued delay. I would watch NVAX from the sidelines for now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":97,"commentSize":7,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}